Free Newsletter
Forest Labs gets Lexapro protection
How does Forest Labs spell relief? P-A-T-E-N-T. A federal court has validated the company's Lexapro protection, safeguarding that blockbuster antidepressant and antianxiety drug through 2012. The court also intervened to stop Teva Pharmaceuticals from launching a generic version of Lexapro, which is Forest's top seller at $2 billion per year.
- check out the release
Related Articles:
FDA OKs generic Lexapro. Report
Lundbeck chair hits exit. Report
Forest Labs dumps failed stroke drug program. Report
More stories about Teva Pharmaceutical Patent H. Lundbeck Lexapro Forest Laboratories antidepressant
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: